Search Tag: Landiolol
2024 12 Mar
An overview of landiolol, a potent and cardioselective beta-blocker offering a promising addition to the armamentarium for managing acute cardiac conditions for rapid and effective rate control with minimal adverse effects. Cardiac emergencies present complex challenges in emergency medical settings, requiring prompt and effective management...Read more
2023 13 Dec
At the end of November 2023, AOP Orphan Pharmaceuticals GmbH ( AOP Health ), an Austrian pharmaceutical company based in Vienna, received authorization from the Canadian Health Authority (Health Canada) for its ultra-short-acting, cardioselective β1-blocker Landiolol. The drug is used in intensive care to treat atrial fibrillation and atrial flutter...Read more
2023 30 Nov
An overview of vasopressor management, current evidence on its use, when to initiate vasopressor therapy for best possible patient outcome and a discussion regarding the use of landiolol in septic patients with persistent tachycardia. Optimising Vasopressin Initiation in Septic Shock Patients with septic shock, and especially...Read more
2023 30 Nov
An overview of vasopressor management, current evidence on its use, when to initiate vasopressor therapy for best possible patient outcome and a discussion regarding the use of landiolol in septic patients with persistent tachycardia. Optimising Vasopressin Initiation in Septic Shock Patients with septic shock, and especially...Read more
2023 13 Oct
Vasopressin and landiolol are critical therapies for ensuring the vascular and cardiac systems are as close to optimal conditions as possible during septic shock. Better cardiovascular management in septic shock can help improve septic shock management. Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response...Read more
2022 08 Dec
A summary of a symposium organised by AOP Health with presentations from Ricard Ferrer, Vall d’Hebron University Hospital, Barcelona, Spain; Bruno Levy, Centre Hospitalier Universitaire de Nancy, CHU Nancy · Réanimation Médicale Brabois, France; and Michael Fries, St. Vincenz Krankenhaus Limburg, Department of Anesthesiology, Germany....Read more
2022 16 Mar
A summary of data regarding the use of landiolol as a potential immunomodulator in septic patients and its effectiveness and safety in the management of new-onset postoperative atrial fibrillation (POAF). Cardiovascular Dysfunction and Sepsis Cardiovascular dysfunction is a common complication of sepsis. Approximately 40 to 50% of patients...Read more
2021 30 Sep
In 2020, the ultra-short acting beta-blocker landiolol was first included in the ESC guidelines with a class I recommendation. The recommendations were based on study results demonstrating the rapid response, efficacy, and safety of this drug. At a recent symposium, during 2021 Heart Failure World Congress, cardiologists were invited to present...Read more
2021 22 Feb
The 2020 ESC Guidelines and the addition of Landiolol An overview of the updated guidelines for the diagnosis and management of atrial fibrillation, developed in association with the European Association for Cardio-Thoracic Surgery. T he European Society of Cardiology (ESC) provides a range of scientific and educational activities,...Read more
2020 08 Oct
Almost half of the patients with sepsis suffer from myocardial depression and a reduced ejection fraction. Sepsis can also cause changes in circulating volume, vascular tone, and coronary blood flow, all of which affect heart function and heart rate. Serum catecholamine levels and direct measurements of renal sympathetic nerve activity have shown...Read more
2020 11 Aug
COVID-19 affects the myocardium and myocarditis and cardiac injury is a common condition among hospitalised patients. Landiolol, a new ultra-short acting, intravenous most β 1 selective blocker, can help reduce inflammation and provide therapeutic benefits. Influenza, bacterial pneumonias, respiratory infections and viruses...Read more